-
In this episode, a16z partners Jorge Conde and Jay Rughani sit down with Sajith Wickramasekara, CEO and cofounder of Benchling, to unpack the evolution of Benchling from idea to transformative software platform.
-
Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health.
-
Jonathan Lim, chairman and CEO of Erasca, joins Jorge Conde, general partner at a16z. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making.
-
Today, we are thrilled to announce our investment in Alchemy as they work to better connect our life sciences and healthcare delivery systems and solve these supply-demand mismatches in the pharmaceutical value chain. Alchemy has emerged to empower the long tail of independent providers with the physical, clinical, and digital infrastructure they need to fully serve their patient communities effectively, and profitably.
-
If these modalities have proven to be so effective (in some cases, even curative) against cancer, is there a role for them outside oncology, in the treatment of chronic diseases that might also be driven by a population of bad-actor cells? Arda Therapeutics is building upon exactly this bold hypothesis.
-
Vijay Pande, general partner, and Daisy Wolf, investing partner, join host Steph Smith on this crossover episode of the a16z podcast.
-
Marta Bralic Kerns, founder and CEO of Pomelo Care, joins Will Shrank, MD, a16z Bio + Health venture partner. Together, they talk about the innovator’s dilemma with building in the Medicaid space
-
Nikita Singareddy, cofounder and CEO of Fortuna Health, joins Will Shrank, MD, a16z Bio + Health venture partner. This is the second episode in our Medicaid Matters series.
-
GCTx is flipping the entire iPSC differentiation paradigm on its head. Rather than manually iterating through a limited set of differentiation protocols, the Human TFome technology platform instead deploys large-scale combinatorial screening to discover new hypotheses and new protocols that are as-yet unknown to even the best biologists.
-
Over the next three episodes, we’re going to talk about why Medicaid matters, and the potential for technology to make it easier for enrollees to access and utilize the program. Our first guest is Mark Smith, MD, Clinical Professor of Medicine at UCSF.
-
Ambience cofounder Nikhil Buduma discusses how to build vertical applications with AI models, including in health care, and why tech expertise isn't enough.
-
Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast.
-
Casey Means, MD, a Stanford-trained physician, cofounder of Levels, and author of the new book Good Energy, joins Vijay Pande, PhD, founding partner of a16z Bio + Health.
-
Half of prescribed medications are never taken, and 88% of Americans are metabolically unhealthy. Despite spending 20% of our GDP on healthcare—twice that of any other developed nation—our outcomes still lag behind. In t...
-
Consumers are effectively a new class of payor. And a number of opportunities exist to build solutions for those consumers (aka these new “micro payors”) to fund, navigate, and manage their healthcare purchases.
-
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z. This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI.
-
Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, PhD, general partner at a16z Bio + Health.
-
Whereas we historically have viewed the low adoption of software as a liability, we now view that as an asset—we don't face the same sunk cost bias that might be slowing other industries down from taking full advantage of the latest AI innovations.
-
Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.
-
Vijay Pande walks us through two decades of applying software engineering and AI to biotech and health care — from Folding@Home through AlphaFold and more.
-
Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health.
-
In this episode, a follow-up to our episode Grand Challenges in Healthcare AI, Julie Yoo and Vijay Pande, a16z general partners, answer audience questions about AI applications in healthcare.
-
John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joins Jorge Conde, general partner at a16z Bio + Health.
-
Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health.
-
Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.
-
Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.
-
Recently, we invested in Function Health, a company that embodies the vision and excitement we had when writing those theses. The one piece we underestimated is the current state of latent demand among consumers for a new approach to healthcare and longevity.
-
This medical home is exactly what knownwell is building – and scaling. Through a hybrid virtual and in-person care model, knownwell offers both primary care as well as longitudinal specialty care, inclusive of weight management, diabetes care, medication (and side effect) management, multi-disciplinary nutritional counseling, and behavioral health services.
-
The most impactful way to fix healthcare is through improving the consumer experience, which has been largely ignored to date. In today’s modern world where you can order groceries, buy flight tickets, and wire money from your phone, taking care of yourself and navigating the healthcare system remains impossibly hard.
-
In this episode, originally recorded for the a16z Podcast, host Steph Smith interviews Pushmeet Kohli, DeepMind's VP of Research focused on AI for science. They are joined by a16z Bio + Health founding partner Vijay Pand...
-
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health.
-
Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.
-
There is perhaps nowhere more exciting or impactful to build such tools than in healthcare—where progress is often so constrained by human expertise. Valar Labs is taking on exactly this challenge, and bringing AI into the toolbox for better cancer care.
-
As Ozempic, Wegovy, Mounjaro, and Zepbound capture the healthcare spotlight, we’ve developed a series of episodes that go beyond the headlines and take you into conversations with the specialists. Our first guest is Carolyn Jasik, MD, Chief Medical Officer at Omada Health.
-
Vineeta Agarwala, MD, PhD, joins Luke Timmerman's The Long Run podcast on stage at the Life Science Innovation Northwest Conference.
-
The stakes are high. The opportunities are profound. From the creation of new medicines to bolstering national defense, this is our vision for the AI-enabled future.
-
Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health. Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab.
-
Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.
-
Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.
-
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.
-
This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.
-
Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.
-
Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
-
Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.
-
Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
-
Scribe Therapeutics cofounder and CEO Ben Oakes joins a16z Bio + Health founding general partner Vijay Pande.
-
The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. But how can biotech teams effectively communicate to investors and partners how they will, with each round of financing, incrementally reduce the risks of discovering and developing successful new drugs?
-
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
-
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.
-
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.
-
Today's episode features the cofounders of Tome Biosciences, Rahul Kakkar, CEO of Tome, and John Finn, CSO. They are joined by Jorge Conde, general partner at a16z Bio + Health.
-
We have long believed that AI will fundamentally reshape biotech and healthcare, positioning us at the brink of an AI-driven Industrial Revolution. But when will we see this payoff? Put more boldly, when will the majority of new drugs be designed with AI?
-
Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit. Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences.
-
All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.
-
Bio Eats World is now Raising Health! On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.
-
Today, we refocus these efforts and expand on them to give you Raising Health. That’s right, Bio Eats World is now Raising Health. While Bio Eats World had a focus on (bio)technological advancements, Raising Health zooms out, focusing not only on the tech, but also the people building it.
-
100% of stock trades used to be made by humans. Today, 80% are made by computer algorithms. AI is about to bring a similar revolution to healthcare. Over the next few decades, at least half of the $4.3 trillion dollar American healthcare industry will be AI-driven.
-
Tome is launching with over $200 million to advance its PGI platform to focus on in vivo and ex vivo applications, with support from a16z Bio + Health, ARCH, GV, Longwood, Polaris and other leading investors. First up on Tome’s in vivo surgical slate: monogenic diseases of the liver. On the ex vivo cell engineering front, Tome is using PGI to rewire cells to cure common, chronic diseases—an area of great promise—with an initial focus on B-cell driven autoimmune diseases.
-
Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health. In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn’t narrowly tailored to one specific task.
-
Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ EXA-cell, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases.
-
Smart energy grids. Voice-first companion apps. Programmable medicines. AI tools for kids. We asked over 40 partners across a16z to preview one big idea they believe will drive innovation in the coming year.
-
Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed "molecular gates."
-
Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health. The conversation explores how AI advancements can revolutionize traditional healthcare models by enhancing efficiency, personalizing care journeys, and integrating real-time data insights.
-
Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.
-
Miriam Vogel, President and CEO of EqualAI, cohost of the podcast In AI we Trust, and Chair to the recently launched National AI Advisory Committee, joins Vijay Pande of Bio + Health.
-
Each new modality needs to find its platform-disease fit—the diseases it is uniquely suited for. But finding fit has increasingly turned into a fight; many have crowded into the same indications. With an expanding arsenal to treat disease, how will patients, clinicians, and the market determine what tool to use?
-
While the Google --> WebMD --> Friend protocol may be a common way to enter into the healthcare system, it is certainly not an optimal one. Most of us are not well-equipped to self-diagnose from a list of possible conditions, and our friends who work in healthcare often don’t have the exact expertise we need.
-
AI trailblazer Suchi Saria, PhD, in conversation with Vijay Pande, sheds light on the winding path that led her to launch Bayesian Health, a bold effort to infuse intelligence into clinical workflows.
-
In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology.
-
While most small molecule drugs bind and inhibit the disease-causing activity of their (typically intracellular) protein targets, Gate Bio instead attacks harmful extracellular proteins by eliminating them at their very root: right where they are produced and secreted from the cell.
-
Together, they talk about how Evan’s work in the lab (ironically, Vijay's lab at Stanford!) translated to the creation of Genesis, which is tackling the problem of drug discovery through AI. They also discuss how the Genesis team is building specifically to carry on work at the intersection of ML, biotech, and chemistry.
-
Olga Troyanskaya, PhD, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology, joins Vijay Pande, founding partner of a16z Bio + Health.
-
As Julie mentions during the episode, there’s international relations, and then there’s CMO/CPO relations. Peter and Reena talk about working together to improve their relationship and the outcomes of their teams, and they get granular about what worked and what didn’t.
-
At the end of the day, even the best AI models will fail if they don’t figure out a way to achieve broad distribution and profitable monetization, so it’s important to understand the psyche of the buyers and decision makers who will determine the fate of your products.
-
With the rapid pace of innovation in AI and other enabling technologies, it is crucial that we have leaders on our team with deep knowledge of how these tools can be applied to drive meaningful change. That is why we are thrilled to welcome Dr. Surya Ganguli as our newest Venture Partner.
-
Surya Ganguli, PhD, an associate professor at Stanford University and a neural dynamics researcher, joins Vijay Pande of Bio + Health.
-
This episode is live from our recent AI Revolutionaries (AIR) conference. In this episode, Daphne Koller, PhD, founder and CEO at insitro and AI expert, chats with Vijay Pande of Bio + Health.
-
Aviv Regev, PhD, the Head and Executive VP of Genentech Research and Early Development, and founding co-chair of the Human Cell Atlas, joins Vijay Pande on Bio Eats World.
-
Insights from leaders at OpenAI, Microsoft, Anthropic, Databricks, Character.AI, Roblox, insitro, and Figma on where we are, where we're going, and the open questions for building the next wave of AI.
-
Daphne Koller, founder and CEO of insitro, discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.
-
Andrew has thought deeply about the implications of integrating AI into many areas of our lives, going so far as to put out a public social media call for people who believe AI is dangerous to speak with him. He and Vijay discussed this, as well as how AI could become foundational to many industries—and what needs to happen to make that future a reality.
-
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
-
Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.
-
In this episode, Dan joins general partner Jorge Conde and investment partner Becky Pferdehirt to discuss how he got started working in chemical biology and chemoproteomics and his experience founding companies, along with leading lab and pharma collaborations.
-
In this exclusive conversation from the Bio + Health BUILD summit, founding partner Ben Horowitz sits down with general partner Jorge Conde.
-
Together, Lloyd and Vijay chatted about how AI could change the practice of medicine, and what the implications are for medical students now and in the future. join Lloyd and Vijay as they discuss AI and medical education—from how students learn to how doctors become licensed.
-
Margaret McKenna, former CTO of Devoted Health and our newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
-
Isaac (Zak) Kohane, MD, PhD, the Chair of the Department of Biomedical Informatics at Harvard Medical School, joins Vijay Pande, founding partner of a16z Bio + Health.
-
We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.
-
Dan Rosenthal, a provider network expert and the newest advisory partner for a16z Bio + Health, joins Julie Yoo, general partner.Together, they talk about the 101 and 201 of provider networks, tactical advice for digital health builders, and how AI could theoretically change the way networks are constructed.
-
Greg Verdine, PhD, is a leader in the discovery, development, and commercialization of new drug modalities, a repeat founder, and the newest venture partner at a16z Bio + Health. He is joined by Vineeta Agarwala and Jorge Conde, general partners at a16z Bio + Health.
-
Jeffrey Kaditz, repeat founder and current founder, CEO, and CTO of Q Bio, joins Vijay Pande, founding partner of a16z Bio + Health.
-
Amy Abernethy, former Principal Deputy Commissioner at the FDA and now the President of Product Development and Chief Medical Officer at Verily Life Sciences, joins Vijay Pande, founding partner of a16z Bio + Health.
-
In this episode, taken from a live a16z event, Bio + Health general partner Vineeta Agarwala moderates a panel of UCSF faculty founders, including Michelle Arkin, Jimmie Ye, and Natalia Jura
-
Today’s episode is with Mark Cuban, founder of multiple businesses, owner of the Dallas Mavericks, one of the sharks on Shark Tank, and cofounder of the Mark Cuban Cost Plus Drug Company.
-
As we have seen the Pomelo team build out their virtual clinic, care model, and software platform, they are dedicated to a few key principles which we believe are absolutely critical to building a scalable company in this space.
-
Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde.
Bio + Healthcare
Biology is evolving from empirical science toward feats of biological engineering, opening the door to exponential improvements in treating, diagnosing, and managing disease. It’s the dawn of the Century of Biology. Get ready for biology to eat the world.
All Bio + Healthcare Content
-
Daphne Koller, founder and CEO of insitro, discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.
-
In this episode, a16z partners Jorge Conde and Jay Rughani sit down with Sajith Wickramasekara, CEO and cofounder of Benchling, to unpack the evolution of Benchling from idea to transformative software platform.
-
Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health.
-
Jonathan Lim, chairman and CEO of Erasca, joins Jorge Conde, general partner at a16z. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making.
-
Vijay Pande, general partner, and Daisy Wolf, investing partner, join host Steph Smith on this crossover episode of the a16z podcast.
-
Marta Bralic Kerns, founder and CEO of Pomelo Care, joins Will Shrank, MD, a16z Bio + Health venture partner. Together, they talk about the innovator’s dilemma with building in the Medicaid space
-
Nikita Singareddy, cofounder and CEO of Fortuna Health, joins Will Shrank, MD, a16z Bio + Health venture partner. This is the second episode in our Medicaid Matters series.
-
Over the next three episodes, we’re going to talk about why Medicaid matters, and the potential for technology to make it easier for enrollees to access and utilize the program. Our first guest is Mark Smith, MD, Clinical Professor of Medicine at UCSF.
-
Ambience cofounder Nikhil Buduma discusses how to build vertical applications with AI models, including in health care, and why tech expertise isn't enough.
-
Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast.
-
Casey Means, MD, a Stanford-trained physician, cofounder of Levels, and author of the new book Good Energy, joins Vijay Pande, PhD, founding partner of a16z Bio + Health.
-
Half of prescribed medications are never taken, and 88% of Americans are metabolically unhealthy. Despite spending 20% of our GDP on healthcare—twice that of any other developed nation—our outcomes still lag behind. In t...
-
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z. This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI.
-
Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, PhD, general partner at a16z Bio + Health.
-
Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.
-
Vijay Pande walks us through two decades of applying software engineering and AI to biotech and health care — from Folding@Home through AlphaFold and more.
-
Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health.
-
In this episode, a follow-up to our episode Grand Challenges in Healthcare AI, Julie Yoo and Vijay Pande, a16z general partners, answer audience questions about AI applications in healthcare.
-
John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joins Jorge Conde, general partner at a16z Bio + Health.
-
Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health.
-
Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.
-
Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.
-
In this episode, originally recorded for the a16z Podcast, host Steph Smith interviews Pushmeet Kohli, DeepMind's VP of Research focused on AI for science. They are joined by a16z Bio + Health founding partner Vijay Pand...
-
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health.
-
Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.
-
As Ozempic, Wegovy, Mounjaro, and Zepbound capture the healthcare spotlight, we’ve developed a series of episodes that go beyond the headlines and take you into conversations with the specialists. Our first guest is Carolyn Jasik, MD, Chief Medical Officer at Omada Health.
-
Vineeta Agarwala, MD, PhD, joins Luke Timmerman's The Long Run podcast on stage at the Life Science Innovation Northwest Conference.
-
Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health. Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab.
-
Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.
-
Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.
-
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.
-
This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.
-
Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.
-
Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
-
Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.
-
Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
-
Scribe Therapeutics cofounder and CEO Ben Oakes joins a16z Bio + Health founding general partner Vijay Pande.
-
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
-
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.
-
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.
-
Today's episode features the cofounders of Tome Biosciences, Rahul Kakkar, CEO of Tome, and John Finn, CSO. They are joined by Jorge Conde, general partner at a16z Bio + Health.
-
Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit. Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences.
-
Bio Eats World is now Raising Health! On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.
-
Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health. In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn’t narrowly tailored to one specific task.
-
Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed "molecular gates."
-
Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health. The conversation explores how AI advancements can revolutionize traditional healthcare models by enhancing efficiency, personalizing care journeys, and integrating real-time data insights.
-
Miriam Vogel, President and CEO of EqualAI, cohost of the podcast In AI we Trust, and Chair to the recently launched National AI Advisory Committee, joins Vijay Pande of Bio + Health.
-
AI trailblazer Suchi Saria, PhD, in conversation with Vijay Pande, sheds light on the winding path that led her to launch Bayesian Health, a bold effort to infuse intelligence into clinical workflows.
-
In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology.
-
Together, they talk about how Evan’s work in the lab (ironically, Vijay's lab at Stanford!) translated to the creation of Genesis, which is tackling the problem of drug discovery through AI. They also discuss how the Genesis team is building specifically to carry on work at the intersection of ML, biotech, and chemistry.
-
Olga Troyanskaya, PhD, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology, joins Vijay Pande, founding partner of a16z Bio + Health.
-
As Julie mentions during the episode, there’s international relations, and then there’s CMO/CPO relations. Peter and Reena talk about working together to improve their relationship and the outcomes of their teams, and they get granular about what worked and what didn’t.
-
Surya Ganguli, PhD, an associate professor at Stanford University and a neural dynamics researcher, joins Vijay Pande of Bio + Health.
-
This episode is live from our recent AI Revolutionaries (AIR) conference. In this episode, Daphne Koller, PhD, founder and CEO at insitro and AI expert, chats with Vijay Pande of Bio + Health.
-
Aviv Regev, PhD, the Head and Executive VP of Genentech Research and Early Development, and founding co-chair of the Human Cell Atlas, joins Vijay Pande on Bio Eats World.
-
Andrew has thought deeply about the implications of integrating AI into many areas of our lives, going so far as to put out a public social media call for people who believe AI is dangerous to speak with him. He and Vijay discussed this, as well as how AI could become foundational to many industries—and what needs to happen to make that future a reality.
-
Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.
-
In this episode, Dan joins general partner Jorge Conde and investment partner Becky Pferdehirt to discuss how he got started working in chemical biology and chemoproteomics and his experience founding companies, along with leading lab and pharma collaborations.
-
In this exclusive conversation from the Bio + Health BUILD summit, founding partner Ben Horowitz sits down with general partner Jorge Conde.
-
Together, Lloyd and Vijay chatted about how AI could change the practice of medicine, and what the implications are for medical students now and in the future. join Lloyd and Vijay as they discuss AI and medical education—from how students learn to how doctors become licensed.
-
Margaret McKenna, former CTO of Devoted Health and our newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
-
Isaac (Zak) Kohane, MD, PhD, the Chair of the Department of Biomedical Informatics at Harvard Medical School, joins Vijay Pande, founding partner of a16z Bio + Health.
-
Dan Rosenthal, a provider network expert and the newest advisory partner for a16z Bio + Health, joins Julie Yoo, general partner.Together, they talk about the 101 and 201 of provider networks, tactical advice for digital health builders, and how AI could theoretically change the way networks are constructed.
-
Greg Verdine, PhD, is a leader in the discovery, development, and commercialization of new drug modalities, a repeat founder, and the newest venture partner at a16z Bio + Health. He is joined by Vineeta Agarwala and Jorge Conde, general partners at a16z Bio + Health.
-
Jeffrey Kaditz, repeat founder and current founder, CEO, and CTO of Q Bio, joins Vijay Pande, founding partner of a16z Bio + Health.
-
Amy Abernethy, former Principal Deputy Commissioner at the FDA and now the President of Product Development and Chief Medical Officer at Verily Life Sciences, joins Vijay Pande, founding partner of a16z Bio + Health.
-
In this episode, taken from a live a16z event, Bio + Health general partner Vineeta Agarwala moderates a panel of UCSF faculty founders, including Michelle Arkin, Jimmie Ye, and Natalia Jura
-
Today’s episode is with Mark Cuban, founder of multiple businesses, owner of the Dallas Mavericks, one of the sharks on Shark Tank, and cofounder of the Mark Cuban Cost Plus Drug Company.
-
Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde.
-
a16z Bio + Health investment partner Becky Pferdehirt chats with Robbie Majzner, MD, an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Stanford, and co-founder of Link Cell Therapies.
-
Today’s episode is with Magi Richani, founder and CEO of Nobell Foods. She is joined by a16z Bio + Health general partner Vijay Pande.
-
This is a crossover episode with The Bioverge Podcast, hosted by Neil Littman. Neil is joined by Vineeta Agarwala, general partner at a16z Bio + Health.
-
Today’s episode is with a16z’s American Dynamism team: Katherine Boyle and David Ulevitch. They are joined by a16z Bio + Health general partner Vijay Pande, and editorial lead Olivia Webb.
-
Today’s episode is with Sean Duffy, cofounder and CEO of Omada Health. He is joined by a16z Bio + Health general partner Julie Yoo and investment partner Jay Rughani.
-
Today’s episode is with Florian Otto, cofounder and CEO of Cedar. He is joined by a16z Bio + Health general partner Julie Yoo.
-
In this episode, Daphne Koller, founder and CEO of insitro, chats with a16z Bio + Health founding partner Vijay Pande.
-
Ben Cravatt, Professor in the Department of Chemistry at the Scripps Research Institute, and Gene Yeo, Professor of Cellular and Molecular Medicine at UCSD, join Vineeta Agarwala, general partner at a16z Bio + Health, and Bryan Faust, investing partner, to talk about their latest published research.
-
In this episode, a16z Bio + Health general partner Julie Yoo chats with Bassett Healthcare Network president and CEO Tommy Ibrahim.
-
In this episode, Jorge Conde, general partner at a16z Bio + Health, talks with Josh Mandel-Brehm, founding CEO of CAMP4.
-
Today’s episode is with Sam Corcos, CEO and cofounder of Levels Health. Sam is joined by Vijay Pande, general partner at a16z Bio + Health.
-
In this episode, Kurt Adams, CEO of Optum Financial, chats with Daisy Wolf, investment partner for a16z Bio + Health, and Marc Andrusko, investment partner for a16z focused on fintech.
-
In this episode, Joe Lonsdale, founder and managing partner at 8VC, joins Vijay Pande, founding partner of a16z Bio + Health, and Olivia Webb, editorial lead.
-
Kevin Parker, cofounder and CEO of Cartography Biosciences, joins Jorge Conde, general partner at a16z Bio + Health, and Olivia Webb, editorial lead.
-
In this episode, Kristen Fortney, cofounder and CEO of BioAge, joins Vijay Pande, founding partner of a16z Bio + Health, and Olivia Webb, editorial lead, to discuss the biology of aging, how she started a company, and some fun things—like how long a hypothetical venture capitalist can expect to live.
-
In this episode, Paul Keckley, the managing editor of the Keckley Report and a health policy expert, joins Julie Yoo, general partner at a16z, and Olivia Webb, editorial lead at a16z.
-
In this episode, Vijay Pande, founding partner of a16z Bio + Health, talks with Jakob Uszkoreit, the cofounder of Inceptive, about the past and future of AI — and how AI can be used to push the science of biology farther.
-
In this episode, Marc Andresseen and Vijay Pande discuss expert AI and its role in healthcare, bio, and more.
-
Cultivated meat: just sci-fi? SCiFi Foods cofounder and CEO Joshua March talks with Bio + Health general partner Vijay Pande and editorial lead Olivia Webb about the challenges, opportunities, and future of cultivated meat.
-
Eric Topol joins a16z Bio + Health general partners Vijay Pande and Vineeta Agarwala and editorial lead Olivia Webb to talk about where AI in healthcare is going, where AI can help patients and providers the most, and what needs to happen to achieve widespread adoption.
-
Bio + Health deal partner Daisy Wolf joins Sarah Thomas, general counsel at Sameday Health, for a fireside chat on the topic of regulation in telehealth—during Covid and on.
-
a16z Bio + Health general partner Vineeta Agarwala chatted with Bobby Franklin, the president and CEO of the National Venture Capital Association.
-
Bio + Health general partner Julie Yoo joins Adam Fein, the CEO of Drug Channels Institute, and Olivia Webb, editorial lead, to discuss the consolidated pharmaceutical system.
-
Bio + Health general partner Vijay Pande discusses the overlap between games and bio with Games general partner Jon Lai.
-
Featuring Suchi Saria, PhD, and the CEO of Bayesian Health; Neri Cohen, MD, PhD, as well as a collaborator with Bayesian Health; and Vineeta Agarwala, MD, PhD, and a16z general partner. Hosted by Olivia Webb.
-
Network effects can be found powering almost every major technology company, from messaging apps and workplace collaboration tools, like Slack and Zoom, to marketplaces, like Airbnb and Instacart to even the internet itself. In this podcast, we look at the role of network effects creator-driven social platforms, with Alexis Ohanian, cofounder from Reddit, Paul Davison, cofounder from Clubhouse, and a16z general partner Andrew Chen, whose new book, "The Cold Start Problem: How to Start and Scale Network Effects" comes out this week (see coldstart.com for more). We cover: how do you cold start and get your first creators? How does your relationship to creators change as you scale? And how is web3 changing the incentives and dynamics around network effects?
-
We were at an inflection point with the COVID pandemic, between old and new tech, science institutions, public health policy, more. So what can we learn from the past for the future? Former head of the FDA Dr. Scott Gottlieb (author of the upcoming new book, Uncontrolled Spread) shares stories from behind the scenes, debating probing ethical and policy questions with a16z co-founder Marc Andreessen and a16z bio general partners Vineeta Agarwala MD, Phd and Vijay Pande PhD.
-
On this episode, we are taking a pulse-check on the state of the intersection between biology, healthcare, and technology with two scientists that sit at another intersection, that of academia and industry: Alexander Mar...
-
In today’s episode we have two short segments, both on bioscience topics.
-
Today, we are thrilled to announce our investment in Alchemy as they work to better connect our life sciences and healthcare delivery systems and solve these supply-demand mismatches in the pharmaceutical value chain. Alchemy has emerged to empower the long tail of independent providers with the physical, clinical, and digital infrastructure they need to fully serve their patient communities effectively, and profitably.
-
If these modalities have proven to be so effective (in some cases, even curative) against cancer, is there a role for them outside oncology, in the treatment of chronic diseases that might also be driven by a population of bad-actor cells? Arda Therapeutics is building upon exactly this bold hypothesis.
-
GCTx is flipping the entire iPSC differentiation paradigm on its head. Rather than manually iterating through a limited set of differentiation protocols, the Human TFome technology platform instead deploys large-scale combinatorial screening to discover new hypotheses and new protocols that are as-yet unknown to even the best biologists.
-
Consumers are effectively a new class of payor. And a number of opportunities exist to build solutions for those consumers (aka these new “micro payors”) to fund, navigate, and manage their healthcare purchases.
-
Whereas we historically have viewed the low adoption of software as a liability, we now view that as an asset—we don't face the same sunk cost bias that might be slowing other industries down from taking full advantage of the latest AI innovations.
-
Recently, we invested in Function Health, a company that embodies the vision and excitement we had when writing those theses. The one piece we underestimated is the current state of latent demand among consumers for a new approach to healthcare and longevity.
-
This medical home is exactly what knownwell is building – and scaling. Through a hybrid virtual and in-person care model, knownwell offers both primary care as well as longitudinal specialty care, inclusive of weight management, diabetes care, medication (and side effect) management, multi-disciplinary nutritional counseling, and behavioral health services.
-
The most impactful way to fix healthcare is through improving the consumer experience, which has been largely ignored to date. In today’s modern world where you can order groceries, buy flight tickets, and wire money from your phone, taking care of yourself and navigating the healthcare system remains impossibly hard.
-
There is perhaps nowhere more exciting or impactful to build such tools than in healthcare—where progress is often so constrained by human expertise. Valar Labs is taking on exactly this challenge, and bringing AI into the toolbox for better cancer care.
-
The stakes are high. The opportunities are profound. From the creation of new medicines to bolstering national defense, this is our vision for the AI-enabled future.
-
The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. But how can biotech teams effectively communicate to investors and partners how they will, with each round of financing, incrementally reduce the risks of discovering and developing successful new drugs?
-
We have long believed that AI will fundamentally reshape biotech and healthcare, positioning us at the brink of an AI-driven Industrial Revolution. But when will we see this payoff? Put more boldly, when will the majority of new drugs be designed with AI?
-
All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.
-
Today, we refocus these efforts and expand on them to give you Raising Health. That’s right, Bio Eats World is now Raising Health. While Bio Eats World had a focus on (bio)technological advancements, Raising Health zooms out, focusing not only on the tech, but also the people building it.
-
100% of stock trades used to be made by humans. Today, 80% are made by computer algorithms. AI is about to bring a similar revolution to healthcare. Over the next few decades, at least half of the $4.3 trillion dollar American healthcare industry will be AI-driven.
-
Tome is launching with over $200 million to advance its PGI platform to focus on in vivo and ex vivo applications, with support from a16z Bio + Health, ARCH, GV, Longwood, Polaris and other leading investors. First up on Tome’s in vivo surgical slate: monogenic diseases of the liver. On the ex vivo cell engineering front, Tome is using PGI to rewire cells to cure common, chronic diseases—an area of great promise—with an initial focus on B-cell driven autoimmune diseases.
-
Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ EXA-cell, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases.
-
Smart energy grids. Voice-first companion apps. Programmable medicines. AI tools for kids. We asked over 40 partners across a16z to preview one big idea they believe will drive innovation in the coming year.
-
Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.
-
Each new modality needs to find its platform-disease fit—the diseases it is uniquely suited for. But finding fit has increasingly turned into a fight; many have crowded into the same indications. With an expanding arsenal to treat disease, how will patients, clinicians, and the market determine what tool to use?
-
While the Google --> WebMD --> Friend protocol may be a common way to enter into the healthcare system, it is certainly not an optimal one. Most of us are not well-equipped to self-diagnose from a list of possible conditions, and our friends who work in healthcare often don’t have the exact expertise we need.
-
While most small molecule drugs bind and inhibit the disease-causing activity of their (typically intracellular) protein targets, Gate Bio instead attacks harmful extracellular proteins by eliminating them at their very root: right where they are produced and secreted from the cell.
-
At the end of the day, even the best AI models will fail if they don’t figure out a way to achieve broad distribution and profitable monetization, so it’s important to understand the psyche of the buyers and decision makers who will determine the fate of your products.
-
With the rapid pace of innovation in AI and other enabling technologies, it is crucial that we have leaders on our team with deep knowledge of how these tools can be applied to drive meaningful change. That is why we are thrilled to welcome Dr. Surya Ganguli as our newest Venture Partner.
-
Insights from leaders at OpenAI, Microsoft, Anthropic, Databricks, Character.AI, Roblox, insitro, and Figma on where we are, where we're going, and the open questions for building the next wave of AI.
-
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
-
We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.
-
As we have seen the Pomelo team build out their virtual clinic, care model, and software platform, they are dedicated to a few key principles which we believe are absolutely critical to building a scalable company in this space.
-
This new era of industrialized bio--enabled by AI as well as an ongoing, foundational shift in biology from empirical science to more engineered approaches--will be the next industrial revolution in human history.
-
How technology will make our healthcare system more intuitive, efficient, and cost-effective.
-
The most impactful companies are built at the frontier, and healthcare is the next frontier. It’s time to put our tech skills to work. The mother of all markets is ripe for disruption.
-
The biotech industry’s appetite for science-native SaaS tools is accelerating and will modernize how medicines are discovered, developed, and distributed.
-
Consider this: most healthcare providers are flying blind when it comes to their finances.
-
Now more than ever, business development is top of mind for biotech founders. Scientific collaborations have always been an essential piece of the drug development ecosystem, enabling small biotech companies to accelerat...
-
We think the biggest company in the world will be a consumer health tech company.
-
The most significant bottleneck in the adoption of healthcare technology to date has been distribution. Over the last decade, generations of digital health companies have struggled to reach escape velocity—not because th...
-
Rick Young is a professor of biology at MIT who studies RNA that is transcribed from the part of the genome that does not code for proteins, known as non-coding DNA. This part of the genome was once referred to as ‘junk...
-
Jennifer Doudna won the 2020 Nobel Prize in Chemistry for her co-discovery of CRISPR/Cas9, a versatile genome editing platform. In the decade since its discovery the toolbox of CRISPR technologies has exploded, acting li...
-
Most of the wildly successful fintech companies haven’t done much in the healthcare sector. Why?
-
COVID has strained our healthcare system, payors are feeling the squeeze of rising costs, and patients are bearing the brunt of the current system's shortcomings. As a result, healthcare is undergoing a transformation, f...
-
Biotech founders face a variety of challenges in building a successful startup. Beyond confronting daunting scientific and technical hurdles, they must develop a strategy to ensure their technology has a compelling business model and is focused on the right problems. Also, they need a plan for how the tech will go the distance — i.e., when to go it alone or seek to partner.
-
2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both...
-
B2C2B — also known as bottom up — has helped companies like Slack, Zoom, Dropbox, and other software companies break into B2B. Now B2C2B is coming to digital health, as a wave of startups are first selling products and s...
-
Digital health is currently one of the fastest growing VC-funded segments, and it’s time to update the GTM playbooks for the current (and future) market.
-
Patients living with cancer are among my personal heroes. They endure difficult treatment regimens for months and years; they trial some of our most unproven novel therapies with hope and optimism. They find themselves i...
-
We’ve now seen multiple trends come to fruition at the intersection of bio and technology over the past decade: A Moore’s Law for bio, thanks to computation; machine learning and AI transforming many areas of bio pharma...
-
As new biological technologies shift the way we make new medicines — from “bespoke craftsmanship to industrialized drug development” — we are seeing bio platforms truly deliver a dizzying array of novel discoveries, tool...
-
We’ve come a long way from having to make the case for artificial intelligence (AI) in biology. Just a few years ago, I argued in The New York Times how fears around the “black box” of AI in medicine are often misplaced...
-
The RNA technology underlying both the Moderna and Pfizer/BioNTech vaccines could give us our fastest ticket out of the COVID-19 pandemic. With their rapid development and the early signs of success, RNA-based therapeuti...
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
We worked hard this year to help tease apart what was hype/ what was real when it came to the buzz and noise around tech trends in the news this year (!) on our podcast show “16 Minutes.” To do so, we went beyond the hea...
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
Many, many pieces have been written about the immense potential of synthetic biology to make manufacturing more sustainable, flexible, and cheaper. Synthetic biology presents the tantalizing opportunity for scientists an...
-
As scientists and particularly as professors, we aim to do big things. We aim to discover new insights, create new tools, and further the scientific endeavor. And occasionally, out of our academic research may come a pro...
-
The entire healthcare system is built around the idea that we can detect, diagnose, and manage disease effectively for patients. This pandemic has been a stress test of that capability, and we have roundly failed that te...
-
There’s been a lot of talk lately about possibilities for treating aging—from blood transfusions from old mice to young, to eradicating “zombie” cells, to taking daily rapamycin and metformin pills to extend your healths...
-
Looking for a job in the 2020s will be very different from looking for a job in the 2000s, or even the 2010s. In this new era of reduced budgets, open-ended hiring freezes, and a shape-shifting workforce of career change...
-
For a downloadable version of this deck, sign up for the a16z Bio Newsletter here.
-
For generations, the field of biology has been largely defined by its discoveries. Now, because many crucial aspects of biology have begun the transition from an empirical science to an engineering discipline, the pendul...
-
The a16z bio newsletter for June/July 2020: Bad policy = bad business models = bad public health; CRISPR for COVID-19; Tracking and tracing disease during pandemics
-
It used to be that when you got sick, your doctor would come to you. But as medical equipment, expertise and knowledge, and the entire modern healthcare system evolved, we created grand institutions to make granting heal...
-
Primary care was meant to be the front door to the healthcare system: the one-stop-shop we rely on for all of our general healthcare needs, and to help us navigate the rest of the convoluted care delivery ecosystem.
-
Every Western institution was unprepared for the coronavirus pandemic, despite many prior warnings. This monumental failure of institutional effectiveness will reverberate for the rest of the decade, but it's not too ear...
-
Developing new drugs is incredibly hard. That’s why, despite superhuman efforts from the industry, we’re still looking at 12-18 months minimum before we can realistically hope for a vaccine for COVID-19, and probably mon...
-
IN THIS ISSUE: How we are staying up to date with COVID-19: Reliable resources in these unpredictable times; Virtual medicine’s mainstream moment: Adoption and development get a big push; Coronavirus tests—what we have and what we need: What diagnostic tests measure and how; Speed of innovation vs safety: Balancing and integrating RCT and RWE; The fight over electronic health data—the sequel: New HHS rules free up patient data.
-
1/ RCTs vs RWE’s has become a heated debate. Some believe that RWE would be cheaper and better, as there’s more data. Others believe that RCTs are the only statistically validated means to test a drug. Who’s right?
-
The need to understand and track the spread of SARS-CoV-2, the virus that causes the disease COVID-19, has highlighted the importance of diagnostic testing. Widespread diagnostic testing is needed not only to identify wh...
-
Editor’s note: As the novel coronavirus spreads, tech developers around the world have assisted in symptom tracking, equipment distribution, data gathering, and much more. Since we’ve been closely tracking this crisis --...
-
Editor's note: This is a list of selected resources on the novel coronavirus (formerly known as as 2019 n-CoV, now known as SARS-CoV-2) that causes COVID-19 disease. The list spans everything from official sources, track...
-
Julie Yoo is a General Partner at Andreessen Horowitz where she leads investments in healthcare technology, with a focus on companies that are modernizing how we access, pay for, and experience the healthcare system.
-
We are at the beginning of a new era for how we treat one of humankind’s oldest and worst foes—cancer. In this talk, given at the annual a16z Summit, Jonathan Lim, CEO and cofounder of Erasca, shows us where we are in ca...
-
IN THIS ISSUE: Bio Fund III: Why bio isn’t the hot new thing—it’s everything; 2020: The Year of Primary Care? Why primary care is getting unbundled and what that means; Novel Coronavirus: What we know/don’t know, where it’s too early to tell, and where tech comes in; The Fight Over Electronic Health Data: What the “letter heard around the healthcare world” means for trends in liquidity, interoperability, and portability of healthcare data...
-
Genetic engineering is in some sense as old as human history, when we first began selectively breeding livestock and crops. Then came the advent of biotech, and our ability to read, copy, edit, and now write DNA directly...
-
Four years ago, when we launched our first bio fund, the idea that software would make an impact in drug discovery sounded like science fiction; the idea it could transform the patient experience in healthcare a fool’s e...
-
You can’t let anyone define you. That’s a mantra Ambassador Susan Rice lives by. From becoming the youngest assistant secretary of state to her role as US Ambassador to the United Nations, she’s learned what it means to...
-
The new discipline of bioengineering is going to dramatically impact how we produce and consume our food. The petroleum era ushered in many of the marquee companies and manufacturing processes of our generation – names s...
-
In this edition of the a16z Bio Newsletter: 16 bio myths and misconceptions; what the first generation of health tech startups learned, what the second did differently, what the coming generation will do best of all; the biggest ways discovery and engineering cultures will increasingly both clash and drive us forward together, in biopharma and healthcare; how synthetic biology found its killer app; and how cell and gene therapies will go mainstream.
-
Bioengineering, once viewed primarily as an academic discipline, is growing up.
-
Tech and biotech just don’t mix. At least that’s the conventional wisdom—which is, in part, why tech and biotech broke up in the early 2000s. Venture capital firms that housed both split their firm into two practices, or...
-
I first met Vineeta fifteen years ago. She was then an undergrad in one of the most challenging graduate-level classes at Stanford—Chem 275, Advanced Statistical Mechanics. Students dreaded this famously difficult class,...
-
The federal agency known as the FDA, or the Food and Drug Administration, was born over a 100 years ago—at the turn of the industrial revolution, in a time of enormous upheaval and change, and rapidly emerging technology...
-
Editor's note: Quartz asked some of the boldest thinkers how they envision the future for their The World in 50 Years series, with various experts across fields answering questions about the future of work and the econom...
-
Editor's note: Quartz asked some of the boldest thinkers how they envision the future for their The World in 50 Years series, with various experts across fields answering questions about the future of work and the econom...
-
Editor's note: Quartz asked some of the boldest thinkers how they envision the future for their The World in 50 Years series, with various experts across fields answering questions about the future of work and the econom...
-
Biology is Eating the World: A Manifesto.
-
Our best tools for understanding and manipulating biology have historically been observation and experimentation. Then, we developed the ability to “read” and “write” in biology. And now, the convergence of biology with...
-
The idea of reverse engineering biology seems like a paradox. How could we ever reverse engineer anything for which we didn’t “invent” the original technology? Radios, bridges, computers—all these are human-made, built f...
-
One of the defining characteristics in an industrial revolution is the fundamental shift from a bespoke, artisan process to an industrialized, engineerable, repeatable one. In this video, general partner on the Bio Fund...
-
We are entering a new era of engineering our own biology—which means we now have an entirely new therapeutic arsenal to treat disease. But these complex new tools also come with new challenges. Below are some of the big topics and current questions in the evolution of gene therapy.
-
We are at the beginning of a new era, where biology has shifted from an empirical science to an engineering discipline. After a millennia of using man-made approaches for controlling or manipulating biology, we have fina...
Dive Deeper
Want more a16z Bio + Health?
Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.